Diabetic women: Inpatient mortality risk before SARS-CoV-2

Carrondo, Cristina

doi:10.1016/j.obmed.2022.100413

Obesity Medicine

2022

DOI: 10.1016/j.obmed.2022.100413

|View full text |Cite

Diabetic women: Inpatient mortality risk before SARS-CoV-2

Cristina Carrondo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiorespiratory complications were defined as the adverse outcome and dependent variable that assumed the values: 0 (without infection) and 1 (with infection). Independent variables were selected from variables previously reported 4,16 as follows:…”

mentioning

confidence: 99%

“…(2) The three stages of severity of main disease; 4,15 O ver the past decade, type 2 diabetes mellitus (T2DM) has become a growing worldwide epidemic. 1,2 In 2015, approximately 415 million adults (aged 20-79 years) had T2DM and it is estimated that number will be 629 million by 2045.…”

mentioning

confidence: 99%

“…In Portugal, hospital admission rates for 88-870 adults increased 82.7% between 2006 and 2015, with acute myocardial infarction being the leading cause of hospitalization. 4 Studies [5][6][7] have reported that cardiorespiratory complications are more prevalent in people with diabetes, particularly in older men. Among the most frequent cardiorespiratory complications in T2DM are arrhythmias and sudden death, coronary heart disease, cardiomyopathy, cerebrovascular disease, and peripheral artery disease.…”

mentioning

confidence: 99%

“…Another study 14 showed that duration (GIS27); neoplasm, malignant: lungs, bronchi, or mediastinum (RES13); and neoplasm, malignant: stomach (GIS30). For all comorbidities, I considered the three stages; 4,15 (4) Treatment type: surgical and medical treatment (according to the DRG criteria).…”

mentioning

confidence: 99%

“…Cardiorespiratory risk 4,15 was explicitly assessed according to the relationship between the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) principal and secondary diagnosis codes and defined as (i) a patient at risk for a specific complication and (ii) a patient with evidence of a potential complication during hospitalization.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Disease Staging: Prevalence of Cardiorespiratory Complications in Type 2 Diabetes Mellitus

Carrondo¹

2022

Clin Med Res

View full text Add to dashboard Cite

The incidence of cardiorespiratory complications in diabetic patients is a major concern for healthcare organizations and providers in Portugal. The objectives of this study were (1) to study the prevalence of cardiorespiratory complications during hospitalization in the diabetic population and (2) to identify their associated factors.Methods: This is a cross-sectional study and included 7,347 diabetic patients admitted to all specialty services enrolled between January 1, 2018 and December 31, 2018 in 32 public hospitals in Portugal. Hospital discharge summary data and both Disease-Related Diagnosis Groups and Disease Staging were used. Descriptive statistical analysis was used where the distribution and rates of cardiorespiratory complications were calculated. Logistic regression using the risk adjustment model was used to calculate the associated risk factors for cardiorespiratory complications. Results:The total rate of cardiorespiratory complications was 18.2% cardiorespiratory complications; in women it was 21.5% and in men 15.6%. The comorbidity of congestive heart failure (98.0%) was significantly higher (P<0.001) among patients undergoing medical treatment, and the comorbidities bacterial pneumonia and coronary artery disease without prior coronary revascularization were significantly higher (63.9%, 45.1%, and 33.4%, P<0.001).Discussion: The use of different therapies to control glucose levels and the absence of antibiotic prophylaxis during medical treatment may account for these data.Conclusions: Cardiorespiratory complications were higher in women than in men and in those who received medical treatment. Comorbidities such as congestive heart failure, such as bacterial pneumonia and coronary artery disease without prior coronary revascularization were identified as risk factors.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Disease Staging: Prevalence of Cardiorespiratory Complications in Type 2 Diabetes Mellitus

Carrondo¹

2022

Clin Med Res

View full text Add to dashboard Cite

show abstract

Frequency of Mortality and Adverse Outcomes of COVID-19 in Hospitalized Type 2 Diabetics with a History of Sitagliptin or Metformin Use

Raji,

Rashidi,

Moradi

et al. 2024

Jundishapur J Chronic Dis Care

View full text Add to dashboard Cite

Background: The relationship between various blood glucose-lowering treatments for type 2 diabetes mellitus (T2DM) and the mortality and complication rates of COVID-19 infection holds significant relevance. Objectives: This retrospective study aimed to investigate the clinical progression of COVID-19 in T2DM patients previously treated with sitagliptin, metformin, or a combination of both. Methods: The study reviewed the medical records of T2DM patients with COVID-19 who had received treatment with sitagliptin, metformin, or both. Participants were selected from those admitted to Naft Hospital in Ahvaz, Iran, from March 2020 to March 2022. Data on mortality and adverse outcomes related to COVID-19 were gathered from the medical records. Results: The study included 529 diabetic patients treated with metformin (n = 197), sitagliptin (n = 231), or both (n = 101) for a minimum of three months. The overall mortality rate among diabetic patients was 15.1%, with the metformin group showing the highest mortality rate at 28.9% (P < 0.0001). Significant differences were observed among the three treatment groups in terms of the frequency of acute respiratory failure (P < 0.0001), stroke (P = 0.002), pulmonary embolism (P < 0.0001), and the necessity for ICU admission (P < 0.0001). Nonetheless, the incidence of myocardial infarction did not significantly differ between the groups. Conclusions: The findings suggest that sitagliptin use for blood sugar control in T2DM patients may help reduce adverse outcomes and the risk of death due to COVID-19. Mortality and morbidity rates were found to be higher in patients treated with metformin compared to those in the other groups.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Diabetic women: Inpatient mortality risk before SARS-CoV-2

Cited by 2 publications

References 38 publications

Disease Staging: Prevalence of Cardiorespiratory Complications in Type 2 Diabetes Mellitus

Disease Staging: Prevalence of Cardiorespiratory Complications in Type 2 Diabetes Mellitus

Frequency of Mortality and Adverse Outcomes of COVID-19 in Hospitalized Type 2 Diabetics with a History of Sitagliptin or Metformin Use

Contact Info

Product

Resources

About